A new belly injection reportedly shrank the most dangerous kind of fat by 12% in early human testing.
Story Highlights
- Participants receiving CBL-514 saw a 12.01% average drop in visceral fat on magnetic resonance imaging scans, while placebo rose 5.68%.
- The studies used randomized, placebo-controlled Phase 2 designs, with repeat injections over up to 12 weeks.
- A published Phase 2 trial showed significant reduction of abdominal subcutaneous fat compared with placebo.
- Follow-up occurred four weeks after the last dose; longer-term durability is not yet established in the public record.
What the early trials actually measured
Researchers tested CBL-514 as a series of lower-abdominal injections every three weeks for up to 12 weeks, with doses reported up to 600 milligrams. Four weeks after the last treatment, magnetic resonance imaging scans reportedly showed a 12.01% average drop in visceral fat for the treatment group, and a 5.68% increase for placebo. Randomized, placebo-controlled Phase 2 designs increase confidence in the treatment signal by comparing outcomes with a sham arm under the same schedule.
Visceral fat sits deep in the abdomen, wrapped around the liver, pancreas, and intestines. It is not the pinchable fat under the skin. Many doctors see visceral fat as more harmful than subcutaneous fat because it tracks with insulin resistance, fatty liver, and heart risk. Showing change by magnetic resonance imaging matters because it directly images tissue volumes instead of guessing from weight or waist size alone.
Published evidence on subcutaneous fat change
A separate Phase 2 trial, already published, documented a clear drop in subcutaneous abdominal fat over the treated area. In that randomized, single-blind, placebo-controlled study, CBL-514 beat placebo on fat-volume reduction at four and eight weeks, with strong statistical results. That paper did not center on visceral fat, but it does show the drug can change fat tissue volumes where it is injected, which supports the overall concept of a regional fat effect.
Trial listings on the federal registry describe similar CBL-514 studies with single-blind and placebo-controlled designs, sample sizes in the dozens to low hundreds, and abdominal treatment regions. These entries help confirm the trial structure and timelines described in public reporting. They also anchor the program in standard development steps for aesthetic and metabolic relevance, even though definitive health outcomes are not the immediate focus.
How to read a 12% drop in deep belly fat
The 12% number will grab headlines. It also lines up with what lifestyle studies suggest: when people lose about 10% of visceral fat, insulin resistance markers can improve over time. That does not prove this injection will deliver the same health gains, but it shows why targeting visceral fat is a serious scientific goal and not just a cosmetic plan. Magnetic resonance imaging makes the number more credible than a bathroom scale would.
NEW TREATMENT: An experimental injection called CBL-514 slashed dangerous visceral fat — the deep abdominal fat wrapped around internal organs — by 12% in early human trials, while patients on a placebo saw their visceral fat increase nearly 6%.
The drug works by selectively… pic.twitter.com/23PMe6LG62
— Fox News Health (@foxnewshealth) October 12, 2026
Americans value straight talk about results, safety, and practical use. These Phase 2 reports show a controlled comparison and a direct imaging readout. That is good method. The follow-up window sits at four weeks post-treatment in the public account, so durability remains to be seen. For now, the take-home is simple: repeated injections of CBL-514 were linked to a meaningful drop in deep belly fat on scans, while placebo moved the other way in the same period.
Why conservative common sense asks for next steps
Practical medicine favors results you can measure, repeat, and apply at scale. The next steps should do exactly that. Publish the full visceral-fat imaging analysis with sample size, confidence intervals, and prespecified endpoints. Track outcomes beyond a month after treatment to see if the effect holds. Test whether changes in visceral fat line up with insulin sensitivity and liver health. These steps would turn an exciting scan result into a clear path for patient benefit.
Sources:
clinicaltrials.gov, pmc.ncbi.nlm.nih.gov, academic.oup.com, cdn.clinicaltrials.gov, fda.gov
